Premium
FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town?
Author(s) -
Milunović Vibor,
Mišura Jakobac Karla,
Kursar Marin,
Mandac Rogulj Inga,
Ostojić Kolonić Slobodanka
Publication year - 2019
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13269
Subject(s) - brentuximab vedotin , medicine , hodgkin lymphoma , regimen , oncology , chemotherapy , clinical endpoint , lymphoma , chemotherapy regimen , randomized controlled trial
ECHELON‐1 study is a randomized open‐labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow‐up of 24.6 months, it has met its primary endpoint the reduction of modified progression‐free survival being 23 percent. However, the beneficial effects have not been seen across all subgroups leading to further questions. The main aim of this review is to tackle these questions to provide the reader with in‐depth insight of pros and cons of this novel, promising but ultimately controversial regimen.